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Protein stability towards aggregation represents a potential 
challenge for the production and administration of 
pharmaceuticals. In particular, aggregation can 
compromise the developability and shelf-life of the 
products, with consequences for yield and safety, 
respectively. In this work, we discuss two novel approaches 
for the analysis of the stability of protein formulations:  
(1) A microfluidic diffusion-sizing platform to analyze protein 
sizes and interactions at high protein concentration directly 
in the solution state with minimal perturbation of the 
sample. The limited dilution of the sample during the 
analysis and the possibility to characterize properties 
directly in the solution state make the technique suitable for 
the analysis of heterogeneous solutions of proteins under 
dynamic equilibrium. We show how the platform represents 
an attractive tool for the analysis of sizes and interactions 
of proteins in both diluted and high-concentration solutions 
during development, manufacturing, and formulation.  
(2) A highly controlled assay of surface-induced protein 
aggregation based on nanoparticles. Protein aggregation is 
often due to heterogeneous nucleation events occurring at 
interfaces, including air/water interface, impurities and 
leachable particles. However, the development of 
screening tools against surface aggregation has been 
hindered by the difficulty in generating a controlled amount 
of surface stress in the formulation as well as in decoupling 
the surface effect from the contribution of hydrodynamic 
flows. In our assay, we leverage the flexibility of polymer 
chemistry to finely tune the properties and amount of 
surfaces provided by the nanoparticles, inducing 
aggregation of soluble peptides and proteins, including 
antibodies, in a time scale of a few hours. This platform 
represents i) an attractive tool for fundamental studies of heterogeneous nucleation events under stagnant and 
flow conditions, and ii) a high-throughput screening assay of the effect of intrinsic and extrinsic variables on 
protein stability towards interface-induced aggregation. 
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Figure 1 – a,b) Microfluidic diffusion sizing 
platform, allowing the measurement of size 
distributions. c,d) Polymeric nanoparticles library 
to screen for interface interactions in protein 
solutions. 
